• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

    10/31/24 7:00:00 AM ET
    $CIA
    $EUDA
    $GOSS
    $LDTC
    Life Insurance
    Finance
    Medical/Nursing Services
    Health Care
    Get the next $CIA alert in real time by email

    MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ:NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Jonathan Javitt, MD, MPH, Founder and Chairman will be discussing its first steps towards acquisition through its HOPE Therapeutics subsidiary of a national network of interventional psychiatry clinics focused on treatment of suicidal depression and PTSD with ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that affect the NMDA receptor of the brain.

    NRx Pharmaceuticals will be presenting on October 31st from 11:25 to 11:55 eastern time.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for NRx Pharmaceuticals, Inc. to:

    [email protected]

    For updates, follow us on Twitter

    Updates to the Day 2 Schedule:

    10:30

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    10:45

    Introduction

    10:50 – 11:20

    Monumental Energy Corp. (OTCQB:MNMRF) (TSXV:MNRG)

    Keynote speaker: Maximilian Sali – VP Corporate Development Founder & Director

    11:25 – 11:55

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

    Keynote speaker: Dr. Jonathan C. Javitt, Chairman and Interim CEO.

    12:00 - 12:30

    Vox Royalty Corp. (NASDAQ:VOXR) (TSX:VOXR)

    Keynote speakers: Kyle Floyd, Chairman & CEO & Chief Investment Officer

    12:35 – 1:05

    Stuhini Explorations, Ltd. (OTCQB:STXPF) (TSXV:STU)

    Keynote speaker: David O'Brien, President & CEO

    1:10 - 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Mike Sheikh, Executive Vice President Business Development

    2:25 – 2:35

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President & CEO, and Jeff Conklin, CFO

    2:40 – 2:50

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    2:55 – 3:05

    Interstellar Communication Holdings

    Keynote speakers: Seda Hewitt, Space Ambassador of IcMercury Harri Laitinen, Lifeguard of IcMercury, and Lijie Zhu, Capitan of icMercury

    3:10 - 3:20

    Sono Group N.V. (OTCQB:SEVCF)

    Keynote speaker: George O'Leary, Managing Director, CEO and CFO

    3:25 - 3:35

    Cyios Corp. (OTC:CYIO)

    Keynote speaker: John O'Shea, Chairman

    3:40 – 3:50

    NurExone Biologic Inc. (OTCQB:NRXBF) (TSXV:NRX)

    Keynote speaker: Dr. Lior Shaltiel, CEO

    3:55 – 4:05

    Evanesce

    Keynote speaker: Douglas Horne, Founder & CEO

    4:10 – 4:20

    LeddarTech Holdings, Inc. (NASDAQ:LDTC)

    Keynote speakers: Frantz Saintellemy – CEO & Chris Stewart, CFO

    4:25 – 4:35

    NCS Multistage Holdings, Inc. (NASDAQ:NCSM)

    Keynote speaker: Ryan Hummer, CEO & Director

    4:40 – 4:50

    EUDA Health Holdings Limited, (NASDAQ:EUDA)

    Keynote speaker: Kelvin Chen, CEO

    About NRx Pharmaceuticals, Inc.

    NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company developing the nation's first network of interventional psychiatry clinics targeting suicidal depression and PTSD through the use of ketamine, transcranial magnetic stimulation, digital therapeutics, and other therapies that target the brain's NMDA receptor. HOPE is committed to offering state of the art lifesaving therapy to the more than 3.4 million Americans who grapple with suicidal depression each year.

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the NRx Pharmaceuticals Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $CIA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • When and where will NRx Pharmaceuticals be presenting?

      NRx Pharmaceuticals (NASDAQ: NRXP) is set to present at the Emerging Growth Conference on October 31, 2024, at 11:25 AM to 11:55 AM Eastern Time.

    • Who will be the keynote speaker for NRx Pharmaceuticals at the conference, and what will be the focus of their presentation?

      Jonathan Javitt, MD, MPH, Founder and Chairman of NRx Pharmaceuticals, will discuss the company's acquisition strategies and the treatments being developed for suicidal depression and PTSD.

    • What is the purpose of the Emerging Growth Conference?

      The Emerging Growth Conference aims to connect small-cap companies with investors and highlights companies with strong management teams and innovative products.

    • What type of health conditions does NRx Pharmaceuticals aim to address with its therapeutics?

      NRx Pharmaceuticals focuses on treating central nervous system disorders, particularly suicidal bipolar depression, chronic pain, and PTSD, through its NMDA platform.

    • What is the role of HOPE Therapeutics in NRx Pharmaceuticals' strategy?

      HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is planning to establish a national network of interventional psychiatry clinics specializing in advanced psychiatric treatments.

    Recent Analyst Ratings for
    $CIA
    $EUDA
    $GOSS
    $LDTC

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Gossamer Bio Inc.
    $GOSS
    6/25/2024$9.00Outperform
    Oppenheimer
    Gossamer Bio Inc.
    $GOSS
    4/5/2024$4.00Outperform
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    7/27/2023$8.00 → $1.25Buy → Neutral
    UBS
    Gossamer Bio Inc.
    $GOSS
    3/7/2023Outperform → Mkt Perform
    Raymond James
    Gossamer Bio Inc.
    $GOSS
    3/1/2023Neutral
    Guggenheim
    Gossamer Bio Inc.
    $GOSS
    12/7/2022Neutral → Underweight
    JP Morgan
    More analyst ratings

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NCS Multistage Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call

      HOUSTON, July 24, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. ("NCS" or the "Company") (NASDAQ:NCSM) will host a conference call to discuss its second quarter 2025 results on Friday, August 1, 2025 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). NCS will issue its second quarter 2025 earnings release the evening prior to the conference call. The conference call will be available via a live audio webcast. Participants who wish to ask questions may register for the call here to receive the dial-in numbers and unique PIN. If you wish to join the conference call but do not plan to ask questions, you may join the listen-only webcast here. It is recommended that participants join

      7/24/25 4:15:23 PM ET
      $NCSM
      Oilfield Services/Equipment
      Energy
    • Nuclear Energy Newcomers Electrify Final Day of EnerCom's 30th Anniversary Energy Investment Conference

      Five Nuclear Companies to Present at EnerCom Denver – The Energy Investment Conference Qualified Investors, Analysts and Energy Industry Professionals Can Register at No Cost at  www.enercomdenver.com  DENVER, July 23, 2025 /PRNewswire/ -- EnerCom, Inc., a leading energy consulting and strategic communications firm, announces an unprecedented lineup of nuclear energy companies scheduled to present on Wednesday, August 20, the final day of the 2025 EnerCom Denver Conference. The event, now in its 30th year, is the largest independent energy investment conference in the U.S., connecting capital with traditional and emerging energy companies from around the world. 

      7/23/25 3:14:00 PM ET
      $AMPY
      $APA
      $BKV
      $BP
      Oil & Gas Production
      Energy
      Integrated oil Companies
      Metal Fabrications
    • EnerCom Denver Releases Full Presenter Lineup for Landmark 30th Energy Investment Conference

      Conference Lineup Features C-Suite Representation from over 75 Confirmed Companies Industry Panel Topics Include The Resurgence of Exploration, Private Companies, The Rise of Asset-Backed Securitization and Private Capital  Qualified Investors, Analysts and Energy Industry Professionals Can Register at www.enercomdenver.com  DENVER, July 14, 2025 /PRNewswire/ -- EnerCom, Inc. is pleased to publish presentation times for participating companies on the conference website for the 30th Annual EnerCom Denver – The Energy Investment Conference, to be held August 17-20, 2025, at the Westin Denver Downtown. The four-day conference provides investors unparalleled access and networking opportunities,

      7/14/25 2:53:00 PM ET
      $AMPY
      $APA
      $BKV
      $BP
      Oil & Gas Production
      Energy
      Integrated oil Companies
      Other Metals and Minerals

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Gossamer Bio with a new price target

      Scotiabank initiated coverage of Gossamer Bio with a rating of Sector Outperform and set a new price target of $11.00

      7/14/25 8:51:47 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

      BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      4/2/25 8:51:11 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Gossamer Bio with a new price target

      Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00

      6/25/24 7:48:05 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Stenberg Jon bought $66,407 worth of Citizens (19,914 units at $3.33), increasing direct ownership by 11% to 198,930 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      6/18/25 2:42:21 PM ET
      $CIA
      Life Insurance
      Finance
    • President & CEO Stenberg Jon bought $129,268 worth of Citizens (34,850 units at $3.71), increasing direct ownership by 20% to 179,016 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      6/2/25 9:53:01 AM ET
      $CIA
      Life Insurance
      Finance
    • Chief Legal Officer Kinlaw Sheryl L bought $8,968 worth of Citizens (2,500 units at $3.59), increasing direct ownership by 4% to 69,289 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      5/29/25 11:00:11 AM ET
      $CIA
      Life Insurance
      Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    SEC Filings

    See more
    • SEC Form 6-K filed by Vox Royalty Corp.

      6-K - VOX ROYALTY CORP. (0001907909) (Filer)

      7/23/25 9:00:45 AM ET
      $VOXR
      Precious Metals
      Basic Materials
    • SEC Form SCHEDULE 13G filed by Citizens Inc.

      SCHEDULE 13G - CITIZENS, INC. (0000024090) (Subject)

      7/17/25 8:12:42 PM ET
      $CIA
      Life Insurance
      Finance
    • SEC Form 6-K filed by Vox Royalty Corp.

      6-K - VOX ROYALTY CORP. (0001907909) (Filer)

      6/30/25 9:00:47 AM ET
      $VOXR
      Precious Metals
      Basic Materials

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Information Officer Guerrero Paula L converted options into 1,278 units of Citizens and covered exercise/tax liability with 312 units of Citizens, increasing direct ownership by 23% to 9,159 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      7/17/25 4:42:59 PM ET
      $CIA
      Life Insurance
      Finance
    • Chief Operations Officer Lewis Bryon Matthew converted options into 1,278 units of Citizens and covered exercise/tax liability with 312 units of Citizens, increasing direct ownership by 8% to 12,695 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      7/17/25 4:33:43 PM ET
      $CIA
      Life Insurance
      Finance
    • Director Taylor Mary disposed of $4 worth of Citizens (1 units at $3.60), increasing direct ownership by 0.28% to 47,790 units (SEC Form 4)

      4 - CITIZENS, INC. (0000024090) (Issuer)

      7/9/25 9:46:57 AM ET
      $CIA
      Life Insurance
      Finance

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Leadership Updates

    Live Leadership Updates

    See more
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

      Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

      5/13/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LeddarTech Reports Annual Shareholder Meeting Results

      QUEBEC CITY, Canada, March 26, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. ("LeddarTech" or the "Corporation") (NASDAQ:LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, LeddarVision™, announces the voting results of its annual general and special meeting of shareholders held on March 26, 2025 (the "Meeting"). Shareholders voted on various proposals and elected directors to the board. Key Highlights of the Meeting 1. Election of Directors: The full slate of six directors was elected to serve until the next annual meeting of shareholders or until a successor is elected or app

      3/26/25 8:18:50 PM ET
      $LDTC
      Computer Software: Prepackaged Software
      Technology
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

      WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

      1/15/25 8:02:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 4:40:26 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 9:55:14 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by LeddarTech Holdings Inc.

      SC 13D/A - LeddarTech Holdings Inc. (0001981462) (Subject)

      8/26/24 1:10:05 PM ET
      $LDTC
      Computer Software: Prepackaged Software
      Technology

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

      Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

      6/21/24 3:17:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CIA
    $EUDA
    $GOSS
    $LDTC
    Financials

    Live finance-specific insights

    See more
    • NCS Multistage Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call

      HOUSTON, July 24, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. ("NCS" or the "Company") (NASDAQ:NCSM) will host a conference call to discuss its second quarter 2025 results on Friday, August 1, 2025 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). NCS will issue its second quarter 2025 earnings release the evening prior to the conference call. The conference call will be available via a live audio webcast. Participants who wish to ask questions may register for the call here to receive the dial-in numbers and unique PIN. If you wish to join the conference call but do not plan to ask questions, you may join the listen-only webcast here. It is recommended that participants join

      7/24/25 4:15:23 PM ET
      $NCSM
      Oilfield Services/Equipment
      Energy
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla

      5/15/25 4:03:00 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

      - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona

      5/15/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care